552 related articles for article (PubMed ID: 19926549)
21. Hypermethylation of the RASSF1A gene in gliomas.
Gao Y; Guan M; Su B; Liu W; Xu M; Lu Y
Clin Chim Acta; 2004 Nov; 349(1-2):173-9. PubMed ID: 15469871
[TBL] [Abstract][Full Text] [Related]
22. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Kostrzewa M; Buchholz E; Manegold C; Lahm H
Lung Cancer; 2006 Oct; 54(1):109-16. PubMed ID: 16893590
[TBL] [Abstract][Full Text] [Related]
23. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer.
Mao WM; Li P; Zheng QQ; Wang CC; Ge MH; Hu FJ; Fang XH; Dong ZM; Ling ZQ
Arch Med Res; 2011 Apr; 42(3):182-8. PubMed ID: 21722812
[TBL] [Abstract][Full Text] [Related]
24. Effect of methylation-associated silencing of the death-associated protein kinase gene on nasopharyngeal carcinoma.
Kong WJ; Zhang S; Guo CK; Wang YJ; Chen X; Zhang SL; Zhang D; Liu Z; Kong W
Anticancer Drugs; 2006 Mar; 17(3):251-9. PubMed ID: 16520653
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic down-regulation of death-associated protein kinase in lung cancers.
Toyooka S; Toyooka KO; Miyajima K; Reddy JL; Toyota M; Sathyanarayana UG; Padar A; Tockman MS; Lam S; Shivapurkar N; Gazdar AF
Clin Cancer Res; 2003 Aug; 9(8):3034-41. PubMed ID: 12912953
[TBL] [Abstract][Full Text] [Related]
26. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
27. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
28. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Köllermann J; Miller K; Schrader M
Clin Cancer Res; 2006 Sep; 12(17):5040-6. PubMed ID: 16951219
[TBL] [Abstract][Full Text] [Related]
29. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
[TBL] [Abstract][Full Text] [Related]
30. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
de Fraipont F; Levallet G; Creveuil C; Bergot E; Beau-Faller M; Mounawar M; Richard N; Antoine M; Rouquette I; Favrot MC; Debieuvre D; Braun D; Westeel V; Quoix E; Brambilla E; Hainaut P; Moro-Sibilot D; Morin F; Milleron B; Zalcman G;
Clin Cancer Res; 2012 May; 18(10):2976-86. PubMed ID: 22434665
[TBL] [Abstract][Full Text] [Related]
31. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer.
Tang X; Khuri FR; Lee JJ; Kemp BL; Liu D; Hong WK; Mao L
J Natl Cancer Inst; 2000 Sep; 92(18):1511-6. PubMed ID: 10995806
[TBL] [Abstract][Full Text] [Related]
32. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
34. Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Wang Y; Zhang D; Zheng W; Luo J; Bai Y; Lu Z
Cancer; 2008 Mar; 112(6):1325-36. PubMed ID: 18286531
[TBL] [Abstract][Full Text] [Related]
35. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
36. Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma.
Hu SL; Kong XY; Cheng ZD; Sun YB; Shen G; Xu WP; Wu L; Xu XC; Jiang XD; Huang DB
Tumori; 2010; 96(5):726-33. PubMed ID: 21302620
[TBL] [Abstract][Full Text] [Related]
37. [Analysis of RASSF1A promoter hypermethylation in serum DNA of non-small cell lung cancer].
Yu ZH; Wang YC; Chen LB; Song Y; Liu C; Xia XY; Lin Q; Ma CY
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):284-7. PubMed ID: 18788633
[TBL] [Abstract][Full Text] [Related]
38. Aberrant methylation of DAPK in long-standing ulcerative colitis and ulcerative colitis-associated carcinoma.
Kuester D; Guenther T; Biesold S; Hartmann A; Bataille F; Ruemmele P; Peters B; Meyer F; Schubert D; Bohr UR; Malfertheiner P; Lippert H; Silver AR; Roessner A; Schneider-Stock R
Pathol Res Pract; 2010 Sep; 206(9):616-24. PubMed ID: 20630662
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
[TBL] [Abstract][Full Text] [Related]
40. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
